French study to reveal who really benefits from obesity drug semaglutide
NCT ID NCT07423481
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study will follow 3,000 French patients with severe or complicated obesity who are taking semaglutide (Wegovy) as part of an early access program. Researchers will track weight changes, treatment patterns, and well-being over time using questionnaires. The goal is to understand which patient characteristics predict success and why some people stop treatment.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- semaglutide (Wegovy)
- What this could lead to
- If successful, this study could help doctors predict which patients with severe obesity will benefit most from semaglutide and guide better treatment strategies.
- What could go wrong
- This is an observational study, not a controlled trial, so it cannot prove cause and effect. Results may be influenced by factors like patient motivation or other treatments.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OBESITY & OVERWEIGHT are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Nantes university hospital
Nantes, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Fiber gummies: a tasty new weapon against obesity?
- Can a diabetes drug improve joint replacement outcomes?
- Can a new pill help older adults lose weight without losing strength?
- Can one avocado a day sharpen the aging brain?
- Can a strict diet put type 2 diabetes into remission?
- Can Weight-Loss surgery alter how medications work?